Clinical trial · Observational
Sarcopenia Risk Screening in Patients With Gastrointestinal Cancer Using SARC-F
Evaluation of the Proportion of Patients With Gastrointestinal Cancer Who Have Symptoms of Sarcopenia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sarcopenia is a syndrome characterized by progressive loss of skeletal muscle mass and strength and is associated with worse outcomes in cancer patients. It can negatively affect prognosis, increase postoperative complications, reduce tolerance to systemic therapy, and impair quality of life. Sarcopenia may be present even in patients with preserved nutritional status or overweight. This study evaluated the proportion of patients with gastrointestinal cancer who were at risk of sarcopenia, as assessed by the SARC-F screening questionnaire, before initiation of systemic treatment and during treatment. Patients with a positive screening result could be referred for further nutritional evaluation and assessment of sarcopenia severity using anthropometric measurements and DXA, according to standard clinical practice.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sarcopenia Screening and Nutritional Referral | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Gastrointestinal Cancer Patients
- description
- Patients with gastrointestinal cancer receiving systemic treatment (adjuvant or metastatic setting) at the Institute of Oncology Ljubljana. Participants will be screened for sarcopenia risk using the SARC-F questionnaire at baseline and during treatment.
- interventionNames
- Other: Sarcopenia Screening and Nutritional Referral
Primary outcomes (1)
- measure
- Proportion of gastrointestinal cancer patients with positive SARC-F screening
- timeFrame
- Baseline (before start of systemic treatment) and during systemic treatment (after 3 months)
- description
- Percentage of patients with gastrointestinal cancer who screen positive for sarcopenia risk using the SARC-F questionnaire. A SARC-F score ≥4 will be considered positive.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (≥18 years) with gastrointestinal cancer * Patients planned for or receiving systemic anticancer treatment (adjuvant treatment or treatment of metastatic disease) * Ability to complete the SARC-F screening questionnaire * Written informed consent provided Exclusion Criteria: * Patients younger than 18 years * Patients unable to complete the questionnaire (e.g., severe cognitive impairment or inability to cooperate) * Patients not eligible for systemic anticancer treatment * Refusal to participate in the study
References
Publications (0)
Data not yet available